Pharmacodynamic evaluation of the epidermal growth factor receptor inhibitor OSI-774 in human epidermis of cancer patients

Clinical Cancer Research

Volumn 9, Issue 7, 2003, Pages 2478-2486

  Malik, Shazli N ^a   Siu, Lillian L ^c   Rowinsky, Eric K ^c   DeGraffenried, Linda ^a   Hammond, Lisa A ^c   Rizzo, Jinee ^c   Bacus, Sarah ^d   Brattain, Michael G ^a   Kreisberg, Jeffrey I ^a   Hidalgo, Manuel ^a,b,e  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^c CTRC Institute for Drug Development   (United States)

^d Ventana QDL Inc   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P27; PROTEIN TYROSINE KINASE INHIBITOR; THREONINE; TYROSINE;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; BLOOD SAMPLING; CELL COUNT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SCREENING; EPIDERMIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PHARMACODYNAMICS; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SKIN BIOPSY; STAINING; UPREGULATION;

ANTINEOPLASTIC AGENTS; HUMANS; IMMUNOHISTOCHEMISTRY; MITOGEN-ACTIVATED PROTEIN KINASES; NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION; SKIN; TYROSINE; UP-REGULATION;

EID: 12444259660     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (20)

1. Yarden Y. The EGFR family and its ligands in human cancer. signaling mechanisms and therapeutic opportunities. Eur. J. Cancer, 37 (Suppl. 4): S3-S8, 2001.
2. Schlessinger, J. Cell signaling by receptor tyrosine kinases. Cell, 103: 211-225, 2000.
3. Mendelsohn, J., and Baselga, J. The EGF receptor family as targets for cancer therapy. Oncogene, 19: 6550-6565, 2000.
4. Hidalgo, M., Siu, L. L., Nemunaitis, J., Rizzo, J., Hammond, L. A., Takimoto, C., Eckhardt, S. G., Tolcher, A., Britten, C. D., Denis, L., et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol., 19: 3267-3279, 2001.
5. Ranson, M., Hammond, L. A., Ferry, D., Kris, M., Tullo, A., Murray, P. I., Miller, V., Averbuch, S., Ochs, J., Morris, C., et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol., 20: 2240-2250, 2002.
6. Baselga, J., Pfister, D., Cooper, M. R., Cohen, R., Burtness, B., Bos, M., D'Andrea, G., Seidman, A., Norton, L., Gunnett, K., et al, Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin, Oncol., 18: 904-914, 2000.
7. Moyer, J, D., Barbacci, E. G., Iwata, K. K., Arnold, L., Boman, B., Cunningham, A., DiOrio, C., Doty, J., Morin, M. J., Moyer, M. P., et al. Induction of apoptosis and cell cycle arrest by CP-358, 774, an inhibitor of epidermal growth factor receptor tyrosine kinase. Cancer Res 57: 4838-4848, 1997,
8. Pollack, V. A., Savage, D. M., Baker, D. A., Tsaparikos, K. E., Sloan, D. E., Moyer,. J. D., Barbacci, E. G., Pustilnik, L. R., Smolarek, T. A., Davis, J. A, et al. Inhibition of epidermal growth factor receptor-associated tyrosine phosphorylation in human carcinomas with CP-358, 774: dynamics of receptor inhibition in situ and antitumor effects in athymic mice. J. Pharmacol. Exp. Ther., 291: 739-748, 1999.
9. Esteva, F. J., Hortobagyi, G. N., Sahin, A. A., Smith, T. L., Chin, D. M., Liang, S. Y., Pusztai, L., Buzdar, A. U., and Bacus, S. S. Expression of erbB/HER receptors, heregulin and P38 in primary breast cancer using quantitative immunohistochemistry. Pathol. Oncol. Res., 7: 171-177, 2001.
10. Kamai, T., Takagi, K., Asami, H., Ito, Y., Arai, K., and Yoshida, K. I. Prognostic significance of p27Kip1 and Ki-67 expression in carcinoma of the renal pelvis and ureter. BJU Int., 86: 14-19, 2000.
11. Shin, D. M., Donato, N. J., Perez-Soler, R., Shin, H. J., Wu, J. Y., Zhang, P., Lawhom, K., Khuri, F. R., Glisson, B. S., Myers, J., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin. Cancer Res., 7: 1204-1213, 2001.
12. Hidalgo, M., Malik, S., Rowinsky, E., Miller, A., Duffey, D., de Grafenried, L., Siu, L., Simmons, C., Kreisberg, J., and Brattain, M. Inhibition of the epidermal growth factor receptor (EGFR) by OSI-774, a specific EGFR inhibitor in malignant and normal tissues of cancer patients. Proc. Am. Soc. Med. Oncol., 20: 281, 2001.
13. Jost, M., Kari, C., and Rodeck, U. The EGF receptor-an essential regulator of multiple epidermal functions. Eur. J. Dermatol., 10: 505-510, 2000.
14. De Potter, I. Y., Poumay, Y., Squillace, K. A., and Pittelkow, M. R. Human EGF receptor (HER) family and heregulin members are differentially expressed in epidermal keratinocytes and modulate differentiation. Exp. Cell Res., 271: 315-328, 2001.
15. Busam, K. J., Capodieci, P., Motzer, R., Kiehn, T., Phelan, D., and Halpern, A. C. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br. J. Dermatol., 144: 1169-1176, 2001.
16. Bishop, P. C., Myers, T., Robey, R., Fry, D. W., Liu, E. T., Blagosklonny, M. V., and Bates, S. E. Differential sensitivity of cancer cells to inhibitors of the epidermal growth factor receptor family. Oncogene, 21: 119-127, 2002.
17. Albanell, J., Rojo, F., Averbuch, S., Feyereislova, A., Mascaro, J. M., Herbst, R., LoRusso, P., Rischin, D., Sauleda, S., Gee, J., et al. Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition. J. Clin. Oncol., 20: 110-124, 2002.
18. Perez-Soler, R, C. A., Huberman, M., Karp, D., Rigas, J., Hammond, L., Rowinsky, E., Preston, G., Ferrante, K. J., Allen, L. F., Nadler, P. I., and Bonomi, P. A phase II trial of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor OSI-774, following platinum-based chemotherapy, in patients (pts) with advanced, EGFRexpressing, non-small cell lung Cancer (NSCLC). Proc. Am. Soc. Med. Oncol., 20: 1235, 2001.
19. Finkler, N. G. A., Crozier, M., Edwards, R., Figueroa, J., Garcia, A., Hainsworth, J., Irwin, D., Silberman, S., Allen, L., Ferrante, F., Fisher, D., and Nadler, P. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proc. Am. Soc. Med. Oncol., 2001. Abs 831.
20. Senzer, N. N. S. D., Siu, L., Agarwala, S., Vokes, E., Hidalgo, M., Silberman, S., Allen, L., Ferrante, K., Fisher, D., Marsolais, C., and Nadler, P. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc. Am. Soc. Med. Oncol., 20:, 2001. Abs 6.